Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial

Launched by KIRBY INSTITUTE ·

Keywords

ClinConnect Summary

This clinical trial is looking at two medicines, moxidectin and ivermectin, to see which one works better to control onchocerciasis, also known as river blindness, in communities in Angola. Both medicines are already approved to treat this disease. The study also checks how these treatments affect other common infections in the area, like intestinal worms and scabies (a skin condition caused by tiny mites). Researchers will give one of these medicines to groups of villages once a year for four years and will collect skin, stool, and blood samples from some people before each treatment to see how well the medicines are working.

People aged 18 and older from these communities may be eligible to participate. If you join, you can expect to receive either moxidectin or ivermectin as part of the community treatment program. The study will also ask about how people feel about the treatments and what makes it easier or harder to carry out these medicine programs. The goal is to find out which medicine better reduces the spread and severity of river blindness and related infections, and to help guide future health policies to eliminate these diseases.

Gender

ALL

Eligibility criteria